John McCamant

John McCamant joined the Medical Technology Stock Letter as Associate Editor in 1987 and was named Editor of this leading investment newsletter in August 2000. Mr. McCamant has spent twenty five years on the front lines of biotechnology investing. As an equities analyst for the American Healthcare Fund, he uncovered investment opportunities and guided investment strategy. At Burrill & Company, a San Francisco-based private merchant bank, he was a lead in raising $75 million for a venture capital fund. Mr. McCamant has established an extensive network that includes contacts throughout the investment banking and venture capital communities. His expertise in biotechnology investments is a subject of media interest. He is frequently consulted and quoted by The Washington Post, Business Week, Reuters, Bloomberg, CBS Marketwatch.

Read More

Medical Technology Stock Letter

The Medical Technology Stock Letter (MTSL) provides solid investment advice based on company and industry fundamentals. Our thirty years of experience in providing investment advice for this unique and volatile sector gives MTSL and YOU the edge. Our insistence on thorough research and of...
Read More

OncoGenex Pharmaceuticals (OGXI)

This biopharmaceutical company has two drug candidates in clinical development across multiple oncology therapeutic areas and a candidate in pre-clinical development. OncoGenex’Pharmaceuticals (OGXI) from The Medical Technology Stock Letter OncoGenex Pharmaceuticals’ (OGXI ) custirsen could dominate second-line hormone resistant prostate cancer (HRPC) therapy. Medivation’s Xtandi has positive...
Read More